Dupilumab (Genetical Recombination) Subcutaneous Injection 200mg Pen (Dupixent® / デュピクセント皮下注200mgペン)

JPY ¥51,600

Japanese Human Anti-Human IL-4/13 Receptor Monoclonal Antibody (Dupilumab (Genetical Recombination) 200mg/1.14mL). Subcutaneous injection for atopic dermatitis, idiopathic chronic urticaria, and bronchial asthma. 1.14mL x 1 pen. Mfd. by Sanofi K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥47,472
10 - 19 12% JPY ¥45,408
20 + 18% JPY ¥42,312
SKU: DUP-200-INJ Category:

Description

Product Overview / 商品概要

Dupixent Subcutaneous Injection 200mg Pen (デュピクセント皮下注200mgペン)
Generic: Dupilumab (Genetical Recombination) / デュピルマブ(遺伝子組換え)
Therapeutic Category: Human Anti-Human IL-4/13 Receptor Monoclonal Antibody / ヒト型抗ヒトIL-4/13受容体モノクローナル抗体
Manufactured by: Sanofi K.K. / サノフィ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Dupilumab (Genetical Recombination) 200mg per 1 vial (1.14mL) / 1製剤(1.14mL)中 デュピルマブ(遺伝子組換え)200mg
Additives: L-Histidine 3.10mg, L-Histidine Hydrochloride Hydrate 0.60mg, L-Arginine Hydrochloride 12.01mg, Sodium Acetate Hydrate 1.50mg, Glacial Acetic Acid 0.19mg, Purified Sucrose 57.00mg, Polysorbate 80 2.28mg / L-ヒスチジン 3.10mg、L-ヒスチジン塩酸塩水和物 0.60mg、L-アルギニン塩酸塩 12.01mg、酢酸ナトリウム水和物 1.50mg、氷酢酸 0.19mg、精製白糖 57.00mg、ポリソルベート80 2.28mg
Appearance: Colorless to slightly yellowish clear liquid or slightly opalescent solution (injection); pH 5.6–6.2; osmolarity ratio approximately 1.0 (relative to physiological saline)
外観: 無色~微黄色の澄明又はわずかに乳白光を呈する液(注射剤)、pH 5.6~6.2、浸透圧比 約1.0(生理食塩液に対する比)

Indications / 効能効果

EN: The following skin diseases inadequately controlled by existing treatments: Atopic dermatitis, Idiopathic chronic urticaria. Bronchial asthma (limited to patients with severe or refractory asthma whose symptoms cannot be controlled by existing treatments)
JA: 既存治療で効果不十分な下記皮膚疾患:アトピー性皮膚炎、特発性の慢性蕁麻疹。気管支喘息(既存治療によっても喘息症状をコントロールできない重症又は難治の患者に限る)

Dosage and Administration / 用法用量

EN: Adults: Initial dose of 600mg subcutaneously, followed by 300mg every 2 weeks. Pediatric patients (6 months and older): Weight-based dosing: 5kg to <15kg: 200mg every 4 weeks; 15kg to <30kg: 300mg every 4 weeks; 30kg to <60kg: initial dose 400mg, then 200mg every 2 weeks; 60kg and above: initial dose 600mg, then 300mg every 2 weeks. Adults: Initial dose of 600mg subcutaneously, followed by 300mg every 2 weeks. Pediatric patients (12 years and older): 30kg to <60kg: initial dose 400mg, then 200mg every 2 weeks; 60kg and above: initial dose 600mg, then 300mg every 2 weeks. Adults and pediatric patients 12 years and older: Initial dose of 600mg subcutaneously, followed by 300mg every 2 weeks. Pediatric patients 6 to <12 years: 15kg to 30kg: 300mg every 4 weeks; over 30kg: 200mg every 2 weeks
JA: 〈アトピー性皮膚炎〉通常、成人にはデュピルマブ(遺伝子組換え)として初回に600mgを皮下投与し、その後は1回300mgを2週間隔で皮下投与する。通常、生後6カ月以上の小児にはデュピルマブ(遺伝子組換え)として体重に応じて以下を皮下投与する。5kg以上15kg未満:1回200mgを4週間隔、15kg以上30kg未満:1回300mgを4週間隔、30kg以上60kg未満:初回に400mg、その後は1回200mgを2週間隔、60kg以上:初回に600mg、その後は1回300mgを2週間隔。〈特発性の慢性蕁麻疹〉通常、成人にはデュピルマブ(遺伝子組換え)として初回に600mgを皮下投与し、その後は1回300mgを2週間隔で皮下投与する。通常、12歳以上の小児にはデュピルマブ(遺伝子組換え)として体重に応じて以下を皮下投与する。30kg以上60kg未満:初回に400mg、その後は1回200mgを2週間隔、60kg以上:初回に600mg、その後は1回300mgを2週間隔。〈気管支喘息〉通常、成人及び12歳以上の小児にはデュピルマブ(遺伝子組換え)として初回に600mgを皮下投与し、その後は1回300mgを2週間隔で皮下投与する。通常、6歳以上12歳未満の小児にはデュピルマブ(遺伝子組換え)として体重に応じて以下を皮下投与する。15kg以上30kg未満:1回300mgを4週間隔、30kg以上:1回200mgを2週間隔

Contraindications / 禁忌

EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 30700AMX00125
Sales Started: November 2025 / 2025年11月
Classification Code: 87449
Storage: Store at 2–8°C. Do not freeze. / 凍結を避け、2~8℃にて保存
Shelf Life: 36 months / 36ヵ月

Packaging / 包装

Main Package (for sale): 1.14mL x 1 pen / 1.14mL×1本
Other Available Packages (by special order): 1.14mL x 1 pen

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Dupilumab (Genetical Recombination) Subcutaneous Injection 200mg Pen (Dupixent® / デュピクセント皮下注200mgペン)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Dupilumab (Genetical Recombination) Subcutaneous Injection 200mg Pen (Dupixent®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.